Astrazeneca Glogal: "AstraZeneca initiates phase III immunotherapy study for MEDI4736 in patients with lung cancer", , 8 May 2014 (2014-05-08), XP002733499, Retrieved from the Internet: URL:http://www.astrazeneca.com/Media/Press -releases/Article/20140508--astrazeneca-in itiates-phase-iii-immunotherapy-study-MEDI 4736 [retrieved on 2014-12-08] (B1)

EP-A1- 2 172 219 (B1)

Lutky J et al.: "A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors", Journal of clinical oncology , vol. 32, no. 15 Suppl. 20 May 2014 (2014-05-20), page 3001, XP002733501, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/conten t/abstract/32/15_suppl/3001 [retrieved on 2014-12-08] (B1)

WO-A1-2013/079174 (B1)

SHENG YAO ET AL: "Advances in targeting cell surface signalling molecules for immune modulation", NATURE REVIEWS DRUG DISCOVERY, vol. 12, no. 2, 1 February 2013 (2013-02-01), pages 130-146, XP055157248, ISSN: 1474-1776, DOI: 10.1038/nrd3877 (B1)

Villaruz L et al.: "Immunotherapy in lung cancer", Transl lung Cancer Res , vol. 3, no. 1 1 February 2014 (2014-02-01), pages 2-14, XP002733500, Retrieved from the Internet: URL:http://www.tlcr.org/article/view/1772/ 2722 [retrieved on 2014-12-08] (B1)

WO-A1-2011/066389 (B1)

Medimmune LLC: "A Phase 1/2 Study to Evaluate MEDI4736", Clinical trials , 14 September 2012 (2012-09-14), XP002733502, Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show/NCT 01693562 [retrieved on 2014-12-05] (B1)